<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1988-08-01" modified="2017-05-10" version="205">
<accession>P08069</accession>
<accession>B1B5Y2</accession>
<accession>Q14CV2</accession>
<accession>Q9UCC0</accession>
<name>IGF1R_HUMAN</name>
<protein>
<recommendedName>
<fullName>Insulin-like growth factor 1 receptor</fullName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Insulin-like growth factor I receptor</fullName>
<shortName>IGF-I receptor</shortName>
</alternativeName>
<cdAntigenName>CD221</cdAntigenName>
<component>
<recommendedName>
<fullName>Insulin-like growth factor 1 receptor alpha chain</fullName>
</recommendedName>
</component>
<component>
<recommendedName>
<fullName>Insulin-like growth factor 1 receptor beta chain</fullName>
</recommendedName>
</component>
</protein>
<gene>
<name type="primary">IGF1R</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1986" name="EMBO J." volume="5" first="2503" last="2512">
<title>Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.</title>
<authorList>
<person name="Ullrich A."/>
<person name="Gray A."/>
<person name="Tam A.W."/>
<person name="Yang-Feng T."/>
<person name="Tsubokawa M."/>
<person name="Collins C."/>
<person name="Henzel W."/>
<person name="Bon T.L."/>
<person name="Kathuria S."/>
<person name="Chen E."/>
<person name="Jacobs S."/>
<person name="Francke U."/>
<person name="Ramachandran J."/>
<person name="Fujita-Yamaguchi Y."/>
</authorList>
<dbReference type="PubMed" id="2877871"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>PROTEIN SEQUENCE OF 31-56; 446-453; 503-524; 561-579; 668-672 AND 721-729</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="1992" name="J. Biol. Chem." volume="267" first="10759" last="10763">
<title>Insulin-like growth factor I receptor gene structure.</title>
<authorList>
<person name="Abbot A.M."/>
<person name="Bueno R."/>
<person name="Pedrini M.T."/>
<person name="Murray J.M."/>
<person name="Smith R.J."/>
</authorList>
<dbReference type="PubMed" id="1316909"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="submission" date="2008-02" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Nagase T."/>
<person name="Kikuno R.F."/>
<person name="Yamakawa H."/>
<person name="Ohara O."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<source>
<tissue>Fetal brain</tissue>
</source>
</reference>
<reference key="4">
<citation type="submission" date="2003-06" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS MET-388 AND HIS-605</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2006" name="Nature" volume="440" first="671" last="675">
<title>Analysis of the DNA sequence and duplication history of human chromosome 15.</title>
<authorList>
<person name="Zody M.C."/>
<person name="Garber M."/>
<person name="Sharpe T."/>
<person name="Young S.K."/>
<person name="Rowen L."/>
<person name="O'Neill K."/>
<person name="Whittaker C.A."/>
<person name="Kamal M."/>
<person name="Chang J.L."/>
<person name="Cuomo C.A."/>
<person name="Dewar K."/>
<person name="FitzGerald M.G."/>
<person name="Kodira C.D."/>
<person name="Madan A."/>
<person name="Qin S."/>
<person name="Yang X."/>
<person name="Abbasi N."/>
<person name="Abouelleil A."/>
<person name="Arachchi H.M."/>
<person name="Baradarani L."/>
<person name="Birditt B."/>
<person name="Bloom S."/>
<person name="Bloom T."/>
<person name="Borowsky M.L."/>
<person name="Burke J."/>
<person name="Butler J."/>
<person name="Cook A."/>
<person name="DeArellano K."/>
<person name="DeCaprio D."/>
<person name="Dorris L. III"/>
<person name="Dors M."/>
<person name="Eichler E.E."/>
<person name="Engels R."/>
<person name="Fahey J."/>
<person name="Fleetwood P."/>
<person name="Friedman C."/>
<person name="Gearin G."/>
<person name="Hall J.L."/>
<person name="Hensley G."/>
<person name="Johnson E."/>
<person name="Jones C."/>
<person name="Kamat A."/>
<person name="Kaur A."/>
<person name="Locke D.P."/>
<person name="Madan A."/>
<person name="Munson G."/>
<person name="Jaffe D.B."/>
<person name="Lui A."/>
<person name="Macdonald P."/>
<person name="Mauceli E."/>
<person name="Naylor J.W."/>
<person name="Nesbitt R."/>
<person name="Nicol R."/>
<person name="O'Leary S.B."/>
<person name="Ratcliffe A."/>
<person name="Rounsley S."/>
<person name="She X."/>
<person name="Sneddon K.M.B."/>
<person name="Stewart S."/>
<person name="Sougnez C."/>
<person name="Stone S.M."/>
<person name="Topham K."/>
<person name="Vincent D."/>
<person name="Wang S."/>
<person name="Zimmer A.R."/>
<person name="Birren B.W."/>
<person name="Hood L."/>
<person name="Lander E.S."/>
<person name="Nusbaum C."/>
</authorList>
<dbReference type="PubMed" id="16572171"/>
<dbReference type="DOI" id="10.1038/nature04601"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1991" name="Biochem. Biophys. Res. Commun." volume="177" first="1113" last="1120">
<title>Analysis of the human type I insulin-like growth factor receptor promoter region.</title>
<authorList>
<person name="Cooke D.W."/>
<person name="Bankert L.A."/>
<person name="Roberts C.T. Jr."/>
<person name="Leroith D."/>
<person name="Casella S.J."/>
</authorList>
<dbReference type="PubMed" id="1711844"/>
<dbReference type="DOI" id="10.1016/0006-291X(91)90654-P"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1993" name="Biochemistry" volume="32" first="13531" last="13536">
<title>Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification.</title>
<authorList>
<person name="Kasuya J."/>
<person name="Paz I.B."/>
<person name="Maddux B.A."/>
<person name="Goldfine I.D."/>
<person name="Hefta S.A."/>
<person name="Fujita-Yamaguchi Y."/>
</authorList>
<dbReference type="PubMed" id="8257688"/>
<dbReference type="DOI" id="10.1021/bi00212a019"/>
</citation>
<scope>PROTEIN SEQUENCE OF 31-45 AND 741-750</scope>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="1993" name="Oncogene" volume="8" first="3403" last="3410">
<title>A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.</title>
<authorList>
<person name="Lee S.-T."/>
<person name="Strunk K.M."/>
<person name="Spritz R.A."/>
</authorList>
<dbReference type="PubMed" id="8247543"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Melanocyte</tissue>
</source>
</reference>
<reference key="10">
<citation type="journal article" date="1991" name="Biochemistry" volume="30" first="48" last="54">
<title>Interaction of the alpha beta dimers of the insulin-like growth factor I receptor is required for receptor autophosphorylation.</title>
<authorList>
<person name="Tollefsen S.E."/>
<person name="Stoszek R.M."/>
<person name="Thompson K."/>
</authorList>
<dbReference type="PubMed" id="1846292"/>
<dbReference type="DOI" id="10.1021/bi00215a008"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1993" name="Biochem. J." volume="290" first="419" last="426">
<title>Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity.</title>
<authorList>
<person name="Soos M.A."/>
<person name="Field C.E."/>
<person name="Siddle K."/>
</authorList>
<dbReference type="PubMed" id="8452530"/>
<dbReference type="DOI" id="10.1042/bj2900419"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="2655" last="2661">
<title>Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3).</title>
<authorList>
<person name="Kato H."/>
<person name="Faria T.N."/>
<person name="Stannard B."/>
<person name="Roberts C.T. Jr."/>
<person name="LeRoith D."/>
</authorList>
<dbReference type="PubMed" id="7679099"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="15639" last="15643">
<title>Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.</title>
<authorList>
<person name="Craparo A."/>
<person name="O'Neill T.J."/>
<person name="Gustafson T.A."/>
</authorList>
<dbReference type="PubMed" id="7541045"/>
<dbReference type="DOI" id="10.1074/jbc.270.26.15639"/>
</citation>
<scope>INTERACTION WITH IRS1; SHC1 AND PIK3R1</scope>
<scope>MUTAGENESIS OF TYR-980 AND LYS-1033</scope>
<scope>PHOSPHORYLATION AT TYR-980</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1997" name="Biochem. J." volume="327" first="209" last="215">
<title>Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting.</title>
<authorList>
<person name="Bailyes E.M."/>
<person name="Nave B.T."/>
<person name="Soos M.A."/>
<person name="Orr S.R."/>
<person name="Hayward A.C."/>
<person name="Siddle K."/>
</authorList>
<dbReference type="PubMed" id="9355755"/>
<dbReference type="DOI" id="10.1042/bj3270209"/>
</citation>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1997" name="Biochem. J." volume="327" first="765" last="771">
<title>14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor.</title>
<authorList>
<person name="Furlanetto R.W."/>
<person name="Dey B.R."/>
<person name="Lopaczynski W."/>
<person name="Nissley S.P."/>
</authorList>
<dbReference type="PubMed" id="9581554"/>
<dbReference type="DOI" id="10.1042/bj3270765"/>
</citation>
<scope>INTERACTION WITH 14-3-3 PROTEINS</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1997" name="Mol. Cell. Endocrinol." volume="129" first="121" last="126">
<title>Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues.</title>
<authorList>
<person name="Federici M."/>
<person name="Porzio O."/>
<person name="Zucaro L."/>
<person name="Fusco A."/>
<person name="Borboni P."/>
<person name="Lauro D."/>
<person name="Sesti G."/>
</authorList>
<dbReference type="PubMed" id="9202395"/>
<dbReference type="DOI" id="10.1016/S0303-7207(97)04050-1"/>
</citation>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="17">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="24095" last="24101">
<title>Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor.</title>
<authorList>
<person name="Dey B.R."/>
<person name="Spence S.L."/>
<person name="Nissley P."/>
<person name="Furlanetto R.W."/>
</authorList>
<dbReference type="PubMed" id="9727029"/>
<dbReference type="DOI" id="10.1074/jbc.273.37.24095"/>
</citation>
<scope>INTERACTION WITH SOCS1 AND SOCS2</scope>
</reference>
<reference key="18">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="31640" last="31643">
<title>beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor.</title>
<authorList>
<person name="Lin F.-T."/>
<person name="Daaka Y."/>
<person name="Lefkowitz R.J."/>
</authorList>
<dbReference type="PubMed" id="9822622"/>
<dbReference type="DOI" id="10.1074/jbc.273.48.31640"/>
</citation>
<scope>INTERACTION WITH ARRB1 AND ARRB2</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1999" name="Exp. Cell Res." volume="253" first="1" last="6">
<title>The IGF-I receptor in cancer research.</title>
<authorList>
<person name="Baserga R."/>
</authorList>
<dbReference type="PubMed" id="10579905"/>
<dbReference type="DOI" id="10.1006/excr.1999.4667"/>
</citation>
<scope>FUNCTION IN CANCER</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1999" name="Mol. Cell. Biol." volume="19" first="6217" last="6228">
<title>Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis.</title>
<authorList>
<person name="Wang J."/>
<person name="Dai H."/>
<person name="Yousaf N."/>
<person name="Moussaif M."/>
<person name="Deng Y."/>
<person name="Boufelliga A."/>
<person name="Swamy O.R."/>
<person name="Leone M.E."/>
<person name="Riedel H."/>
</authorList>
<dbReference type="PubMed" id="10454568"/>
<dbReference type="DOI" id="10.1128/MCB.19.9.6217"/>
</citation>
<scope>INTERACTION WITH GRB10</scope>
<scope>MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281 AND TYR-1346</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2000" name="Biochem. Biophys. Res. Commun." volume="278" first="38" last="43">
<title>Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor.</title>
<authorList>
<person name="Dey B.R."/>
<person name="Furlanetto R.W."/>
<person name="Nissley P."/>
</authorList>
<dbReference type="PubMed" id="11071852"/>
<dbReference type="DOI" id="10.1006/bbrc.2000.3762"/>
</citation>
<scope>INTERACTION WITH SOCS3</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2000" name="Biochem. Biophys. Res. Commun." volume="279" first="955" last="960">
<title>Autophosphorylation of the insulin-like growth factor I receptor cytoplasmic domain.</title>
<authorList>
<person name="Lopaczynski W."/>
<person name="Terry C."/>
<person name="Nissley P."/>
</authorList>
<dbReference type="PubMed" id="11162456"/>
<dbReference type="DOI" id="10.1006/bbrc.2000.4046"/>
</citation>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="15099" last="15105">
<title>Mechanism of STAT3 activation by insulin-like growth factor I receptor.</title>
<authorList>
<person name="Zong C.S."/>
<person name="Chan J."/>
<person name="Levy D.E."/>
<person name="Horvath C."/>
<person name="Sadowski H.B."/>
<person name="Wang L.H."/>
</authorList>
<dbReference type="PubMed" id="10747872"/>
<dbReference type="DOI" id="10.1074/jbc.M000089200"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF STAT3</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2002" name="Cancer Res." volume="62" first="2942" last="2950">
<title>Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.</title>
<authorList>
<person name="Hellawell G.O."/>
<person name="Turner G.D."/>
<person name="Davies D.R."/>
<person name="Poulsom R."/>
<person name="Brewster S.F."/>
<person name="Macaulay V.M."/>
</authorList>
<dbReference type="PubMed" id="12019176"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="39684" last="39695">
<title>Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.</title>
<authorList>
<person name="Pandini G."/>
<person name="Frasca F."/>
<person name="Mineo R."/>
<person name="Sciacca L."/>
<person name="Vigneri R."/>
<person name="Belfiore A."/>
</authorList>
<dbReference type="PubMed" id="12138094"/>
<dbReference type="DOI" id="10.1074/jbc.M202766200"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Mol. Cell. Biol." volume="22" first="2345" last="2365">
<title>RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix.</title>
<authorList>
<person name="Hermanto U."/>
<person name="Zong C.S."/>
<person name="Li W."/>
<person name="Wang L.H."/>
</authorList>
<dbReference type="PubMed" id="11884618"/>
<dbReference type="DOI" id="10.1128/MCB.22.7.2345-2365.2002"/>
</citation>
<scope>INTERACTION WITH RACK1</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="13325" last="13332">
<title>Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).</title>
<authorList>
<person name="Galvan V."/>
<person name="Logvinova A."/>
<person name="Sperandio S."/>
<person name="Ichijo H."/>
<person name="Bredesen D.E."/>
</authorList>
<dbReference type="PubMed" id="12556535"/>
<dbReference type="DOI" id="10.1074/jbc.M211398200"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH MAP3K5</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2003" name="Proc. Natl. Acad. Sci. U.S.A." volume="100" first="8247" last="8252">
<title>Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor.</title>
<authorList>
<person name="Girnita L."/>
<person name="Girnita A."/>
<person name="Larsson O."/>
</authorList>
<dbReference type="PubMed" id="12821780"/>
<dbReference type="DOI" id="10.1073/pnas.1431613100"/>
</citation>
<scope>UBIQUITINATION BY MDM2</scope>
<scope>INTERACTION WITH MDM2</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2004" name="Cancer Res." volume="64" first="236" last="242">
<title>Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.</title>
<authorList>
<person name="Girnita A."/>
<person name="Girnita L."/>
<person name="del Prete F."/>
<person name="Bartolazzi A."/>
<person name="Larsson O."/>
<person name="Axelson M."/>
</authorList>
<dbReference type="PubMed" id="14729630"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-03-2522"/>
</citation>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="24412" last="24419">
<title>{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.</title>
<authorList>
<person name="Girnita L."/>
<person name="Shenoy S.K."/>
<person name="Sehat B."/>
<person name="Vasilcanu R."/>
<person name="Girnita A."/>
<person name="Lefkowitz R.J."/>
<person name="Larsson O."/>
</authorList>
<dbReference type="PubMed" id="15878855"/>
<dbReference type="DOI" id="10.1074/jbc.M501129200"/>
</citation>
<scope>INTERACTION WITH ARRB1 AND ARRB2</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2005" name="J. Biol. Chem." volume="280" first="31830" last="31840">
<title>JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3.</title>
<authorList>
<person name="Yadav A."/>
<person name="Kalita A."/>
<person name="Dhillon S."/>
<person name="Banerjee K."/>
</authorList>
<dbReference type="PubMed" id="15998644"/>
<dbReference type="DOI" id="10.1074/jbc.M501316200"/>
</citation>
<scope>INTERACTION WITH STAT3</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="25869" last="25874">
<title>Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant.</title>
<authorList>
<person name="Slaaby R."/>
<person name="Schaeffer L."/>
<person name="Lautrup-Larsen I."/>
<person name="Andersen A.S."/>
<person name="Shaw A.C."/>
<person name="Mathiasen I.S."/>
<person name="Brandt J."/>
</authorList>
<dbReference type="PubMed" id="16831875"/>
<dbReference type="DOI" id="10.1074/jbc.M605189200"/>
</citation>
<scope>FUNCTION</scope>
<scope>FORMATION OF A HYBRID RECEPTOR WITH INSR</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2007" name="Biochem. Biophys. Res. Commun." volume="358" first="1136" last="1141">
<title>The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis.</title>
<authorList>
<person name="McElroy B."/>
<person name="Powell J.C."/>
<person name="McCarthy J.V."/>
</authorList>
<dbReference type="PubMed" id="17524361"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2007.05.062"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>PROTEOLYTIC PROCESSING</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2007" name="Eur. J. Cancer" volume="43" first="1895" last="1904">
<title>The insulin-like growth factor 1 receptor in cancer: old focus, new future.</title>
<authorList>
<person name="Hartog H."/>
<person name="Wesseling J."/>
<person name="Boezen H.M."/>
<person name="van der Graaf W.T."/>
</authorList>
<dbReference type="PubMed" id="17624760"/>
<dbReference type="DOI" id="10.1016/j.ejca.2007.05.021"/>
</citation>
<scope>REVIEW ON IGF1R IN CANCER</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2008" name="Mol. Cell" volume="31" first="438" last="448">
<title>Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.</title>
<authorList>
<person name="Daub H."/>
<person name="Olsen J.V."/>
<person name="Bairlein M."/>
<person name="Gnad F."/>
<person name="Oppermann F.S."/>
<person name="Korner R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Stemmann O."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="18691976"/>
<dbReference type="DOI" id="10.1016/j.molcel.2008.07.007"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="36">
<citation type="journal article" date="2009" name="J. Biol. Chem." volume="284" first="24106" last="24114">
<title>The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.</title>
<authorList>
<person name="Saegusa J."/>
<person name="Yamaji S."/>
<person name="Ieguchi K."/>
<person name="Wu C.Y."/>
<person name="Lam K.S."/>
<person name="Liu F.T."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="19578119"/>
<dbReference type="DOI" id="10.1074/jbc.M109.013201"/>
</citation>
<scope>BINDING TO IGF1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND IGF1</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2009" name="Mol. Cell. Proteomics" volume="8" first="1751" last="1764">
<title>Large-scale proteomics analysis of the human kinome.</title>
<authorList>
<person name="Oppermann F.S."/>
<person name="Gnad F."/>
<person name="Olsen J.V."/>
<person name="Hornberger R."/>
<person name="Greff Z."/>
<person name="Keri G."/>
<person name="Mann M."/>
<person name="Daub H."/>
</authorList>
<dbReference type="PubMed" id="19369195"/>
<dbReference type="DOI" id="10.1074/mcp.M800588-MCP200"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2010" name="PLoS ONE" volume="5" first="E11332" last="E11332">
<title>Development and validation of a method for profiling post-translational modification activities using protein microarrays.</title>
<authorList>
<person name="Del Rincon S.V."/>
<person name="Rogers J."/>
<person name="Widschwendter M."/>
<person name="Sun D."/>
<person name="Sieburg H.B."/>
<person name="Spruck C."/>
</authorList>
<dbReference type="PubMed" id="20596523"/>
<dbReference type="DOI" id="10.1371/journal.pone.0011332"/>
</citation>
<scope>SUMOYLATION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2010" name="Sci. Signal." volume="3" first="RA3" last="RA3">
<title>Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.</title>
<authorList>
<person name="Olsen J.V."/>
<person name="Vermeulen M."/>
<person name="Santamaria A."/>
<person name="Kumar C."/>
<person name="Miller M.L."/>
<person name="Jensen L.J."/>
<person name="Gnad F."/>
<person name="Cox J."/>
<person name="Jensen T.S."/>
<person name="Nigg E.A."/>
<person name="Brunak S."/>
<person name="Mann M."/>
</authorList>
<dbReference type="PubMed" id="20068231"/>
<dbReference type="DOI" id="10.1126/scisignal.2000475"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="40">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="41852" last="41861">
<title>Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation.</title>
<authorList>
<person name="Mao Y."/>
<person name="Shang Y."/>
<person name="Pham V.C."/>
<person name="Ernst J.A."/>
<person name="Lill J.R."/>
<person name="Scales S.J."/>
<person name="Zha J."/>
</authorList>
<dbReference type="PubMed" id="21994939"/>
<dbReference type="DOI" id="10.1074/jbc.M111.288514"/>
</citation>
<scope>UBIQUITINATION AT LYS-1168 AND LYS-1171</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2012" name="J. Biol. Chem." volume="287" first="12491" last="12500">
<title>Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.</title>
<authorList>
<person name="Fujita M."/>
<person name="Ieguchi K."/>
<person name="Davari P."/>
<person name="Yamaji S."/>
<person name="Taniguchi Y."/>
<person name="Sekiguchi K."/>
<person name="Takada Y.K."/>
<person name="Takada Y."/>
</authorList>
<dbReference type="PubMed" id="22351760"/>
<dbReference type="DOI" id="10.1074/jbc.M111.304170"/>
</citation>
<scope>BINDING TO IGF1</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND IGF1</scope>
</reference>
<reference key="42">
<citation type="journal article" date="1998" name="Nature" volume="394" first="395" last="399">
<title>Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor.</title>
<authorList>
<person name="Garrett T.P."/>
<person name="McKern N.M."/>
<person name="Lou M."/>
<person name="Frenkel M.J."/>
<person name="Bentley J.D."/>
<person name="Lovrecz G.O."/>
<person name="Elleman T.C."/>
<person name="Cosgrove L.J."/>
<person name="Ward C.W."/>
</authorList>
<dbReference type="PubMed" id="9690478"/>
<dbReference type="DOI" id="10.1038/28668"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492</scope>
<scope>DISULFIDE BONDS</scope>
<scope>GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2001" name="Nat. Struct. Biol." volume="8" first="1058" last="1063">
<title>Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.</title>
<authorList>
<person name="Favelyukis S."/>
<person name="Till J.H."/>
<person name="Hubbard S.R."/>
<person name="Miller W.T."/>
</authorList>
<dbReference type="PubMed" id="11694888"/>
<dbReference type="DOI" id="10.1038/nsb721"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH AMP-PCP AND PEPTIDE SUBSTRATE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>ENZYME REGULATION</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
<scope>PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2001" name="Structure" volume="9" first="955" last="965">
<title>Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation.</title>
<authorList>
<person name="Pautsch A."/>
<person name="Zoephel A."/>
<person name="Ahorn H."/>
<person name="Spevak W."/>
<person name="Hauptmann R."/>
<person name="Nar H."/>
</authorList>
<dbReference type="PubMed" id="11591350"/>
<dbReference type="DOI" id="10.1016/S0969-2126(01)00655-4"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH ANP</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>ACTIVE SITE</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2002" name="J. Biol. Chem." volume="277" first="38797" last="38802">
<title>Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.</title>
<authorList>
<person name="Munshi S."/>
<person name="Kornienko M."/>
<person name="Hall D.L."/>
<person name="Reid J.C."/>
<person name="Waxman L."/>
<person name="Stirdivant S.M."/>
<person name="Darke P.L."/>
<person name="Kuo L.C."/>
</authorList>
<dbReference type="PubMed" id="12138114"/>
<dbReference type="DOI" id="10.1074/jbc.M205580200"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2003" name="Acta Crystallogr. D" volume="59" first="1725" last="1730">
<title>Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution.</title>
<authorList>
<person name="Munshi S."/>
<person name="Hall D.L."/>
<person name="Kornienko M."/>
<person name="Darke P.L."/>
<person name="Kuo L.C."/>
</authorList>
<dbReference type="PubMed" id="14501110"/>
<dbReference type="DOI" id="10.1107/S0907444903015415"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2007" name="Bioorg. Med. Chem. Lett." volume="17" first="2317" last="2321">
<title>Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).</title>
<authorList>
<person name="Velaparthi U."/>
<person name="Wittman M."/>
<person name="Liu P."/>
<person name="Stoffan K."/>
<person name="Zimmermann K."/>
<person name="Sang X."/>
<person name="Carboni J."/>
<person name="Li A."/>
<person name="Attar R."/>
<person name="Gottardis M."/>
<person name="Greer A."/>
<person name="Chang C.Y."/>
<person name="Jacobsen B.L."/>
<person name="Sack J.S."/>
<person name="Sun Y."/>
<person name="Langley D.R."/>
<person name="Balasubramanian B."/>
<person name="Vyas D."/>
</authorList>
<dbReference type="PubMed" id="17317169"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2007.01.102"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH BENZIMIDAZOLE PYRIDINONE INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2008" name="Bioorg. Med. Chem. Lett." volume="18" first="3641" last="3645">
<title>Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.</title>
<authorList>
<person name="Mayer S.C."/>
<person name="Banker A.L."/>
<person name="Boschelli F."/>
<person name="Di L."/>
<person name="Johnson M."/>
<person name="Kenny C.H."/>
<person name="Krishnamurthy G."/>
<person name="Kutterer K."/>
<person name="Moy F."/>
<person name="Petusky S."/>
<person name="Ravi M."/>
<person name="Tkach D."/>
<person name="Tsou H.R."/>
<person name="Xu W."/>
</authorList>
<dbReference type="PubMed" id="18501599"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.04.044"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286</scope>
<scope>PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2008" name="EMBO J." volume="27" first="1985" last="1994">
<title>Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.</title>
<authorList>
<person name="Wu J."/>
<person name="Li W."/>
<person name="Craddock B.P."/>
<person name="Foreman K.W."/>
<person name="Mulvihill M.J."/>
<person name="Ji Q.S."/>
<person name="Miller W.T."/>
<person name="Hubbard S.R."/>
</authorList>
<dbReference type="PubMed" id="18566589"/>
<dbReference type="DOI" id="10.1038/emboj.2008.116"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH INHIBITOR PQIP</scope>
<scope>SUBUNIT</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ACTIVE SITE</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2009" name="Bioorg. Med. Chem. Lett." volume="19" first="62" last="66">
<title>Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.</title>
<authorList>
<person name="Miller L.M."/>
<person name="Mayer S.C."/>
<person name="Berger D.M."/>
<person name="Boschelli D.H."/>
<person name="Boschelli F."/>
<person name="Di L."/>
<person name="Du X."/>
<person name="Dutia M."/>
<person name="Floyd M.B."/>
<person name="Johnson M."/>
<person name="Kenny C.H."/>
<person name="Krishnamurthy G."/>
<person name="Moy F."/>
<person name="Petusky S."/>
<person name="Tkach D."/>
<person name="Torres N."/>
<person name="Wu B."/>
<person name="Xu W."/>
</authorList>
<dbReference type="PubMed" id="19041240"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2008.11.037"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH 3-CYANOQUINOLINE INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
<scope>PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2009" name="J. Med. Chem." volume="52" first="7360" last="7363">
<title>Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.</title>
<authorList>
<person name="Wittman M.D."/>
<person name="Carboni J.M."/>
<person name="Yang Z."/>
<person name="Lee F.Y."/>
<person name="Antman M."/>
<person name="Attar R."/>
<person name="Balimane P."/>
<person name="Chang C."/>
<person name="Chen C."/>
<person name="Discenza L."/>
<person name="Frennesson D."/>
<person name="Gottardis M.M."/>
<person name="Greer A."/>
<person name="Hurlburt W."/>
<person name="Johnson W."/>
<person name="Langley D.R."/>
<person name="Li A."/>
<person name="Li J."/>
<person name="Liu P."/>
<person name="Mastalerz H."/>
<person name="Mathur A."/>
<person name="Menard K."/>
<person name="Patel K."/>
<person name="Sack J."/>
<person name="Sang X."/>
<person name="Saulnier M."/>
<person name="Smith D."/>
<person name="Stefanski K."/>
<person name="Trainor G."/>
<person name="Velaparthi U."/>
<person name="Zhang G."/>
<person name="Zimmermann K."/>
<person name="Vyas D.M."/>
</authorList>
<dbReference type="PubMed" id="19778024"/>
<dbReference type="DOI" id="10.1021/jm900786r"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH BMS-754807</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2010" name="ACS Med. Chem. Lett." volume="1" first="199" last="203">
<title>Allosteric IGF-1R Inhibitors.</title>
<authorList>
<person name="Heinrich T."/>
<person name="Graedler U."/>
<person name="Boettcher H."/>
<person name="Blaukat A."/>
<person name="Shutes A."/>
</authorList>
<dbReference type="DOI" id="10.1021/ml100044h"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH MSC1609119A-1</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2010" name="Bioorg. Med. Chem. Lett." volume="20" first="5027" last="5030">
<title>Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.</title>
<authorList>
<person name="Sampognaro A.J."/>
<person name="Wittman M.D."/>
<person name="Carboni J.M."/>
<person name="Chang C."/>
<person name="Greer A.F."/>
<person name="Hurlburt W.W."/>
<person name="Sack J.S."/>
<person name="Vyas D.M."/>
</authorList>
<dbReference type="PubMed" id="20675137"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2010.07.045"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH INHIBITORS</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2010" name="Chem. Biol. Drug Des." volume="76" first="100" last="106">
<title>Design of potent IGF1-R inhibitors related to bis-azaindoles.</title>
<authorList>
<person name="Nemecek C."/>
<person name="Metz W.A."/>
<person name="Wentzler S."/>
<person name="Ding F.X."/>
<person name="Venot C."/>
<person name="Souaille C."/>
<person name="Dagallier A."/>
<person name="Maignan S."/>
<person name="Guilloteau J.P."/>
<person name="Bernard F."/>
<person name="Henry A."/>
<person name="Grapinet S."/>
<person name="Lesuisse D."/>
</authorList>
<dbReference type="PubMed" id="20545947"/>
<dbReference type="DOI" id="10.1111/j.1747-0285.2010.00991.x"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH BIS-AZAINDOLE INHIBITOR</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2011" name="Bioorg. Med. Chem. Lett." volume="21" first="2224" last="2228">
<title>Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.</title>
<authorList>
<person name="Lesuisse D."/>
<person name="Mauger J."/>
<person name="Nemecek C."/>
<person name="Maignan S."/>
<person name="Boiziau J."/>
<person name="Harlow G."/>
<person name="Hittinger A."/>
<person name="Ruf S."/>
<person name="Strobel H."/>
<person name="Nair A."/>
<person name="Ritter K."/>
<person name="Malleron J.L."/>
<person name="Dagallier A."/>
<person name="El-Ahmad Y."/>
<person name="Guilloteau J.P."/>
<person name="Guizani H."/>
<person name="Bouchard H."/>
<person name="Venot C."/>
</authorList>
<dbReference type="PubMed" id="21441024"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2011.03.003"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH HYDANTOIN DERIVATIVE</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2011" name="Bioorg. Med. Chem. Lett." volume="21" first="2394" last="2399">
<title>Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.</title>
<authorList>
<person name="Buchanan J.L."/>
<person name="Newcomb J.R."/>
<person name="Carney D.P."/>
<person name="Chaffee S.C."/>
<person name="Chai L."/>
<person name="Cupples R."/>
<person name="Epstein L.F."/>
<person name="Gallant P."/>
<person name="Gu Y."/>
<person name="Harmange J.C."/>
<person name="Hodge K."/>
<person name="Houk B.E."/>
<person name="Huang X."/>
<person name="Jona J."/>
<person name="Joseph S."/>
<person name="Jun H.T."/>
<person name="Kumar R."/>
<person name="Li C."/>
<person name="Lu J."/>
<person name="Menges T."/>
<person name="Morrison M.J."/>
<person name="Novak P.M."/>
<person name="van der Plas S."/>
<person name="Radinsky R."/>
<person name="Rose P.E."/>
<person name="Sawant S."/>
<person name="Sun J.R."/>
<person name="Surapaneni S."/>
<person name="Turci S.M."/>
<person name="Xu K."/>
<person name="Yanez E."/>
<person name="Zhao H."/>
<person name="Zhu X."/>
</authorList>
<dbReference type="PubMed" id="21414779"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2011.02.075"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH 2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2003" name="N. Engl. J. Med." volume="349" first="2211" last="2222">
<title>IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation.</title>
<authorList>
<consortium name="The intrauterine growth retardation (IUGR) study group"/>
<person name="Abuzzahab M.J."/>
<person name="Schneider A."/>
<person name="Goddard A."/>
<person name="Grigorescu F."/>
<person name="Lautier C."/>
<person name="Keller E."/>
<person name="Kiess W."/>
<person name="Klammt J."/>
<person name="Kratzsch J."/>
<person name="Osgood D."/>
<person name="Pfaeffle R."/>
<person name="Raile K."/>
<person name="Seidel B."/>
<person name="Smith R.J."/>
<person name="Chernausek S.D."/>
</authorList>
<dbReference type="PubMed" id="14657428"/>
<dbReference type="DOI" id="10.1056/NEJMoa010107"/>
</citation>
<scope>VARIANTS IGF1RES GLN-138 AND ASN-145</scope>
<scope>CHARACTERIZATION OF VARIANTS IGF1RES GLN-138 AND ASN-145</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2005" name="J. Clin. Endocrinol. Metab." volume="90" first="4679" last="4687">
<title>Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation.</title>
<authorList>
<person name="Kawashima Y."/>
<person name="Kanzaki S."/>
<person name="Yang F."/>
<person name="Kinoshita T."/>
<person name="Hanaki K."/>
<person name="Nagaishi J."/>
<person name="Ohtsuka Y."/>
<person name="Hisatome I."/>
<person name="Ninomoya H."/>
<person name="Nanba E."/>
<person name="Fukushima T."/>
<person name="Takahashi S."/>
</authorList>
<dbReference type="PubMed" id="15928254"/>
<dbReference type="DOI" id="10.1210/jc.2004-1947"/>
</citation>
<scope>VARIANT IGF1RES GLN-739</scope>
<scope>CHARACTERIZATION OF VARIANT IGF1RES GLN-739</scope>
</reference>
<reference key="59">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857; THR-1338 AND VAL-1347</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2015" name="Clin. Endocrinol. (Oxf.)" volume="82" first="704" last="711">
<title>Three novel IGF1R mutations in microcephalic patients with prenatal and postnatal growth impairment.</title>
<authorList>
<person name="Juanes M."/>
<person name="Guercio G."/>
<person name="Marino R."/>
<person name="Berensztein E."/>
<person name="Warman D.M."/>
<person name="Ciaccio M."/>
<person name="Gil S."/>
<person name="Bailez M."/>
<person name="Rivarola M.A."/>
<person name="Belgorosky A."/>
</authorList>
<dbReference type="PubMed" id="25040157"/>
<dbReference type="DOI" id="10.1111/cen.12555"/>
</citation>
<scope>VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND CYS-1337</scope>
<scope>CHARACTERIZATION OF VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND CYS-1337</scope>
</reference>
<comment type="function">
<text>Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.</text>
</comment>
<comment type="function">
<text>When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</text>
</comment>
<comment type="catalytic activity">
<text evidence="15 19 29 34 35 37 40 41 42 48 58">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="19 25 29 34 35 37 38 40 41 42 58">Activated by autophosphorylation at Tyr-1165, Tyr-1161 and Tyr-1166 on the kinase activation loop; phosphorylation at all three tyrosine residues is required for optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807, PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole, 3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine, pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin (PPP), tyrphostin derivatives. While most inhibitors bind to the ATP binding pocket, MSC1609119A-1 functions as allosteric inhibitor and binds close to the DFG motif and the activation loop.</text>
</comment>
<comment type="subunit">
<text evidence="16 17 18 19 20 22 23 26 28 29 32 34 35 36 37 38 41 42 44 47 53 55 56 58">Tetramer of 2 alpha and 2 beta chains linked by disulfide bonds. The alpha chains contribute to the formation of the ligand-binding domain, while the beta chain carries the kinase domain. Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and SHC1 in vitro when autophosphorylated on tyrosine residues. Forms a hybrid receptor with INSR, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts with GRB10. Interacts with RACK1. Interacts with SOCS1, SOCS2 and SOCS3. Interacts with 14-3-3 proteins. Interacts with NMD2. Interacts with MAP3K5. Interacts with STAT3. Found in a ternary complex with IGF1 and ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:19578119, PubMed:22351760).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-475981"/>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-821440">
<id>Q9NZN5</id>
<label>ARHGEF12</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-6378485">
<id>P49913</id>
<label>CAMP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-2906540">
<id>Q64010</id>
<label>Crk</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-1380630">
<id>P41240</id>
<label>CSK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-491549">
<id>P35222</id>
<label>CTNNB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-7902275">
<id>P05019</id>
<label>IGF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-3989070">
<id>P01317</id>
<label>INS</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-751501">
<id>Q9Y2W7</id>
<label>KCNIP3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-926131">
<id>Q9UJU2</id>
<label>LEF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-389668">
<id>Q00987</id>
<label>MDM2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-79464">
<id>P27986</id>
<label>PIK3R1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-968788">
<id>P18031</id>
<label>PTPN1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-297779">
<id>Q06124</id>
<label>PTPN11</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-1000553">
<id>P29353-2</id>
<label>SHC1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-475981"/>
<interactant intactId="EBI-1054248">
<id>Q01995</id>
<label>TAGLN</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="31">Cell membrane</location>
<topology evidence="31">Single-pass type I membrane protein</topology>
</subcellularLocation>
</comment>
<comment type="tissue specificity">
<text evidence="21 49 51 52">Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.</text>
</comment>
<comment type="PTM">
<text evidence="10">Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner; Tyr-1165 is predominantly phosphorylated first, followed by phosphorylation of Tyr-1161 and Tyr-1166. While every single phosphorylation increases kinase activity, all three tyrosine residues in the kinase activation loop (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal activity. Can be autophosphorylated at additional tyrosine residues (in vitro). Autophosphorylated is followed by phosphorylation of juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278 by GSK-3beta restrains kinase activity and promotes cell surface expression, it requires a priming phosphorylation at Ser-1282. Dephosphorylated by PTPN1 (By similarity).</text>
</comment>
<comment type="PTM">
<text evidence="19 23 33 35 43 47">Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-48' and 'Lys-29' linkages, promoting receptor endocytosis and subsequent degradation by the proteasome. Ubiquitination is facilitated by pre-existing phosphorylation.</text>
</comment>
<comment type="PTM">
<text evidence="39">Sumoylated with SUMO1.</text>
</comment>
<comment type="PTM">
<text evidence="31">Controlled by regulated intramembrane proteolysis (RIP). Undergoes metalloprotease-dependent constitutive ectodomain shedding to produce a membrane-anchored 52 kDa C-Terminal fragment which is further processed by presenilin gamma-secretase to yield an intracellular 50 kDa fragment.</text>
</comment>
<comment type="disease" evidence="24 27 45">
<disease id="DI-02747">
<name>Insulin-like growth factor 1 resistance</name>
<acronym>IGF1RES</acronym>
<description>A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels.</description>
<dbReference type="MIM" id="270450"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="13">Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.</text>
</comment>
<comment type="sequence caution" evidence="59">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="BAG11657" version="1"/>
</conflict>
<text>Translation N-terminally shortened.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/IGF1RID40928ch15q26.html"/>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/igf1r/"/>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/IGF-1_receptor"/>
<text>IGF-1 receptor entry</text>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="X04434">
<property type="protein sequence ID" value="CAA28030.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB425196">
<property type="protein sequence ID" value="BAG11657.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY332722">
<property type="protein sequence ID" value="AAP81165.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC055807">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC069029">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC118658">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC118660">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC113610">
<property type="protein sequence ID" value="AAI13611.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC113612">
<property type="protein sequence ID" value="AAI13613.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M69229">
<property type="protein sequence ID" value="AAB59399.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS10378.1"/>
<dbReference type="PIR" id="A25690">
<property type="entry name" value="IGHUR1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000866.1">
<property type="nucleotide sequence ID" value="NM_000875.4"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001278787.1">
<property type="nucleotide sequence ID" value="NM_001291858.1"/>
</dbReference>
<dbReference type="UniGene" id="Hs.643120"/>
<dbReference type="UniGene" id="Hs.714012"/>
<dbReference type="PDB" id="1IGR">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A=31-492"/>
</dbReference>
<dbReference type="PDB" id="1JQH">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A/B/C=979-1286"/>
</dbReference>
<dbReference type="PDB" id="1K3A">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=988-1286"/>
</dbReference>
<dbReference type="PDB" id="1M7N">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=974-1294"/>
</dbReference>
<dbReference type="PDB" id="1P4O">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.50"/>
<property type="chains" value="A/B=974-1294"/>
</dbReference>
<dbReference type="PDB" id="2OJ9">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="2ZM3">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B/C/D=981-1286"/>
</dbReference>
<dbReference type="PDB" id="3D94">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=986-1286"/>
</dbReference>
<dbReference type="PDB" id="3F5P">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286"/>
</dbReference>
<dbReference type="PDB" id="3I81">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.08"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="3LVP">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A/B/C/D=951-1286"/>
</dbReference>
<dbReference type="PDB" id="3LW0">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.79"/>
<property type="chains" value="A/B/C/D=983-1286"/>
</dbReference>
<dbReference type="PDB" id="3NW5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.14"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="3NW6">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="3NW7">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.11"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="3O23">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=982-1286"/>
</dbReference>
<dbReference type="PDB" id="3QQU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A/B/C/D=988-1286"/>
</dbReference>
<dbReference type="PDB" id="4D2R">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=985-1286"/>
</dbReference>
<dbReference type="PDB" id="4XSS">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="F=721-736"/>
</dbReference>
<dbReference type="PDB" id="5FXQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=980-1286"/>
</dbReference>
<dbReference type="PDB" id="5FXR">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=980-1286"/>
</dbReference>
<dbReference type="PDB" id="5FXS">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=980-1286"/>
</dbReference>
<dbReference type="PDB" id="5HZN">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/B/C/D/E/F/G/H=983-1286"/>
</dbReference>
<dbReference type="PDBsum" id="1IGR"/>
<dbReference type="PDBsum" id="1JQH"/>
<dbReference type="PDBsum" id="1K3A"/>
<dbReference type="PDBsum" id="1M7N"/>
<dbReference type="PDBsum" id="1P4O"/>
<dbReference type="PDBsum" id="2OJ9"/>
<dbReference type="PDBsum" id="2ZM3"/>
<dbReference type="PDBsum" id="3D94"/>
<dbReference type="PDBsum" id="3F5P"/>
<dbReference type="PDBsum" id="3I81"/>
<dbReference type="PDBsum" id="3LVP"/>
<dbReference type="PDBsum" id="3LW0"/>
<dbReference type="PDBsum" id="3NW5"/>
<dbReference type="PDBsum" id="3NW6"/>
<dbReference type="PDBsum" id="3NW7"/>
<dbReference type="PDBsum" id="3O23"/>
<dbReference type="PDBsum" id="3QQU"/>
<dbReference type="PDBsum" id="4D2R"/>
<dbReference type="PDBsum" id="4XSS"/>
<dbReference type="PDBsum" id="5FXQ"/>
<dbReference type="PDBsum" id="5FXR"/>
<dbReference type="PDBsum" id="5FXS"/>
<dbReference type="PDBsum" id="5HZN"/>
<dbReference type="ProteinModelPortal" id="P08069"/>
<dbReference type="SMR" id="P08069"/>
<dbReference type="BioGrid" id="109701">
<property type="interactions" value="73"/>
</dbReference>
<dbReference type="DIP" id="DIP-476N"/>
<dbReference type="IntAct" id="P08069">
<property type="interactions" value="54"/>
</dbReference>
<dbReference type="MINT" id="MINT-85902"/>
<dbReference type="STRING" id="9606.ENSP00000268035"/>
<dbReference type="BindingDB" id="P08069"/>
<dbReference type="ChEMBL" id="CHEMBL1957"/>
<dbReference type="DrugBank" id="DB07474">
<property type="generic name" value="3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE"/>
</dbReference>
<dbReference type="DrugBank" id="DB05023">
<property type="generic name" value="ATL1101"/>
</dbReference>
<dbReference type="DrugBank" id="DB05759">
<property type="generic name" value="IMC-A12"/>
</dbReference>
<dbReference type="DrugBank" id="DB05900">
<property type="generic name" value="INSM-18"/>
</dbReference>
<dbReference type="DrugBank" id="DB00047">
<property type="generic name" value="Insulin Glargine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00030">
<property type="generic name" value="Insulin Human"/>
</dbReference>
<dbReference type="DrugBank" id="DB00046">
<property type="generic name" value="Insulin Lispro"/>
</dbReference>
<dbReference type="DrugBank" id="DB00071">
<property type="generic name" value="Insulin Pork"/>
</dbReference>
<dbReference type="DrugBank" id="DB01277">
<property type="generic name" value="Mecasermin"/>
</dbReference>
<dbReference type="DrugBank" id="DB04395">
<property type="generic name" value="Phosphoaminophosphonic Acid-Adenylate Ester"/>
</dbReference>
<dbReference type="DrugBank" id="DB05897">
<property type="generic name" value="rhIGFBP-3"/>
</dbReference>
<dbReference type="DrugBank" id="DB05184">
<property type="generic name" value="XL228"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1801"/>
<dbReference type="iPTMnet" id="P08069"/>
<dbReference type="PhosphoSitePlus" id="P08069"/>
<dbReference type="BioMuta" id="IGF1R"/>
<dbReference type="DMDM" id="124240"/>
<dbReference type="EPD" id="P08069"/>
<dbReference type="MaxQB" id="P08069"/>
<dbReference type="PaxDb" id="P08069"/>
<dbReference type="PeptideAtlas" id="P08069"/>
<dbReference type="PRIDE" id="P08069"/>
<dbReference type="DNASU" id="3480"/>
<dbReference type="Ensembl" id="ENST00000268035">
<property type="protein sequence ID" value="ENSP00000268035"/>
<property type="gene ID" value="ENSG00000140443"/>
</dbReference>
<dbReference type="GeneID" id="3480"/>
<dbReference type="KEGG" id="hsa:3480"/>
<dbReference type="UCSC" id="uc002bul.4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="3480"/>
<dbReference type="DisGeNET" id="3480"/>
<dbReference type="GeneCards" id="IGF1R"/>
<dbReference type="HGNC" id="HGNC:5465">
<property type="gene designation" value="IGF1R"/>
</dbReference>
<dbReference type="HPA" id="CAB010268"/>
<dbReference type="HPA" id="HPA045563"/>
<dbReference type="MalaCards" id="IGF1R"/>
<dbReference type="MIM" id="147370">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="270450">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P08069"/>
<dbReference type="OpenTargets" id="ENSG00000140443"/>
<dbReference type="Orphanet" id="73273">
<property type="disease" value="Growth delay due to insulin-like growth factor I resistance"/>
</dbReference>
<dbReference type="PharmGKB" id="PA29698"/>
<dbReference type="eggNOG" id="KOG4258">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118818"/>
<dbReference type="HOGENOM" id="HOG000038045"/>
<dbReference type="HOVERGEN" id="HBG006134"/>
<dbReference type="InParanoid" id="P08069"/>
<dbReference type="KO" id="K05087"/>
<dbReference type="OMA" id="GYLYRHN"/>
<dbReference type="OrthoDB" id="EOG091G00GE"/>
<dbReference type="PhylomeDB" id="P08069"/>
<dbReference type="TreeFam" id="TF351636"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2404192">
<property type="pathway name" value="Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2428928">
<property type="pathway name" value="IRS-related events triggered by IGF1R"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2428933">
<property type="pathway name" value="SHC-related events triggered by IGF1R"/>
</dbReference>
<dbReference type="SignaLink" id="P08069"/>
<dbReference type="SIGNOR" id="P08069"/>
<dbReference type="ChiTaRS" id="IGF1R">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P08069"/>
<dbReference type="GeneWiki" id="Insulin-like_growth_factor_1_receptor"/>
<dbReference type="GenomeRNAi" id="3480"/>
<dbReference type="PRO" id="PR:P08069"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 15"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000140443"/>
<dbReference type="CleanEx" id="HS_IGF1R"/>
<dbReference type="ExpressionAtlas" id="P08069">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P08069">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0035867">
<property type="term" value="C:alphav-beta3 integrin-IGF-1-IGF1R complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000305"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043231">
<property type="term" value="C:intracellular membrane-bounded organelle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016020">
<property type="term" value="C:membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="AgBase"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="IntAct"/>
</dbReference>
<dbReference type="GO" id="GO:0043559">
<property type="term" value="F:insulin binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005158">
<property type="term" value="F:insulin receptor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043560">
<property type="term" value="F:insulin receptor substrate binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005520">
<property type="term" value="F:insulin-like growth factor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031994">
<property type="term" value="F:insulin-like growth factor I binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005010">
<property type="term" value="F:insulin-like growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043548">
<property type="term" value="F:phosphatidylinositol 3-kinase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006955">
<property type="term" value="P:immune response"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051389">
<property type="term" value="P:inactivation of MAPKK activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008286">
<property type="term" value="P:insulin receptor signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0048009">
<property type="term" value="P:insulin-like growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0038083">
<property type="term" value="P:peptidyl-tyrosine autophosphorylation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0014065">
<property type="term" value="P:phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000305"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048015">
<property type="term" value="P:phosphatidylinositol-mediated signaling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030335">
<property type="term" value="P:positive regulation of cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0045740">
<property type="term" value="P:positive regulation of DNA replication"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051262">
<property type="term" value="P:protein tetramerization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046328">
<property type="term" value="P:regulation of JNK cascade"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007165">
<property type="term" value="P:signal transduction"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="CDD" id="cd00063">
<property type="entry name" value="FN3"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="Gene3D" id="3.80.20.20">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="InterPro" id="IPR003961">
<property type="entry name" value="FN3_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR006211">
<property type="entry name" value="Furin-like_Cys-rich_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR006212">
<property type="entry name" value="Furin_repeat"/>
</dbReference>
<dbReference type="InterPro" id="IPR009030">
<property type="entry name" value="Growth_fac_rcpt_"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR032675">
<property type="entry name" value="L_dom-like"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR000494">
<property type="entry name" value="Rcpt_L-dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR016246">
<property type="entry name" value="Tyr_kinase_insulin-like_rcpt"/>
</dbReference>
<dbReference type="InterPro" id="IPR002011">
<property type="entry name" value="Tyr_kinase_rcpt_2_CS"/>
</dbReference>
<dbReference type="Pfam" id="PF00757">
<property type="entry name" value="Furin-like"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF01030">
<property type="entry name" value="Recep_L_domain"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF000620">
<property type="entry name" value="Insulin_receptor"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00109">
<property type="entry name" value="TYRKINASE"/>
</dbReference>
<dbReference type="SMART" id="SM00060">
<property type="entry name" value="FN3"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00261">
<property type="entry name" value="FU"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF49265">
<property type="entry name" value="SSF49265"/>
<property type="match status" value="4"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF52058">
<property type="entry name" value="SSF52058"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF57184">
<property type="entry name" value="SSF57184"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50853">
<property type="entry name" value="FN3"/>
<property type="match status" value="4"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00239">
<property type="entry name" value="RECEPTOR_TYR_KIN_II"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0165">Cleavage on pair of basic residues</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-1017">Isopeptide bond</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide" evidence="46 50">
<location>
<begin position="1"/>
<end position="30"/>
</location>
</feature>
<feature type="chain" description="Insulin-like growth factor 1 receptor alpha chain" id="PRO_0000016681">
<location>
<begin position="31"/>
<end position="736"/>
</location>
</feature>
<feature type="chain" description="Insulin-like growth factor 1 receptor beta chain" id="PRO_0000016682">
<location>
<begin position="741"/>
<end position="1367"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="12">
<location>
<begin position="741"/>
<end position="935"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="12">
<location>
<begin position="936"/>
<end position="959"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="12">
<location>
<begin position="960"/>
<end position="1367"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 1" evidence="14">
<location>
<begin position="491"/>
<end position="609"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 2" evidence="14">
<location>
<begin position="610"/>
<end position="708"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 3" evidence="14">
<location>
<begin position="735"/>
<end position="828"/>
</location>
</feature>
<feature type="domain" description="Fibronectin type-III 4" evidence="14">
<location>
<begin position="834"/>
<end position="927"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="13">
<location>
<begin position="999"/>
<end position="1274"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="13">
<location>
<begin position="1005"/>
<end position="1013"/>
</location>
</feature>
<feature type="short sequence motif" description="IRS1- and SHC1-binding">
<location>
<begin position="977"/>
<end position="980"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="13 15">
<location>
<position position="1135"/>
</location>
</feature>
<feature type="binding site" description="ATP">
<location>
<position position="1033"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="60">
<location>
<position position="980"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="19 33 35">
<location>
<position position="1161"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="19 33 35">
<location>
<position position="1165"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="19 33 35">
<location>
<position position="1166"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by GSK3-beta" evidence="10">
<location>
<position position="1278"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="11">
<location>
<position position="1282"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="54">
<location>
<position position="51"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="102"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="54">
<location>
<position position="135"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="54">
<location>
<position position="244"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="54">
<location>
<position position="314"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="417"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="438"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="534"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="607"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="622"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="640"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="747"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="756"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="764"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="900"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="12">
<location>
<position position="913"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="33"/>
<end position="52"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="150"/>
<end position="178"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="182"/>
<end position="205"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="192"/>
<end position="211"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="215"/>
<end position="224"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="219"/>
<end position="230"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="231"/>
<end position="239"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="235"/>
<end position="248"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="251"/>
<end position="260"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="264"/>
<end position="276"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="282"/>
<end position="303"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="307"/>
<end position="321"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="324"/>
<end position="328"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="332"/>
<end position="353"/>
</location>
</feature>
<feature type="disulfide bond" evidence="54">
<location>
<begin position="455"/>
<end position="488"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" evidence="43">
<location>
<position position="1168"/>
</location>
</feature>
<feature type="cross-link" description="Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)" evidence="43">
<location>
<position position="1171"/>
</location>
</feature>
<feature type="sequence variant" description="In a renal chromophobe sample; somatic mutation." id="VAR_041424" evidence="30">
<original>V</original>
<variation>L</variation>
<location>
<position position="105"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; has decreased IGF1R function; dbSNP:rs121912426." id="VAR_034891" evidence="24">
<original>R</original>
<variation>Q</variation>
<location>
<position position="138"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; has decreased IGF1R function; dbSNP:rs121912427." id="VAR_034892" evidence="24">
<original>K</original>
<variation>N</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts." id="VAR_076247" evidence="45">
<original>N</original>
<variation>Y</variation>
<location>
<position position="359"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs45445894." id="VAR_018855" evidence="57">
<original>V</original>
<variation>M</variation>
<location>
<position position="388"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34516635." id="VAR_034893" evidence="30">
<original>R</original>
<variation>H</variation>
<location>
<position position="437"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs33958176." id="VAR_034894">
<original>R</original>
<variation>Q</variation>
<location>
<position position="511"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56248469." id="VAR_041425" evidence="30">
<original>R</original>
<variation>H</variation>
<location>
<position position="595"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs45553041." id="VAR_018856" evidence="57">
<original>R</original>
<variation>H</variation>
<location>
<position position="605"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; leads to failure of processing of the IGF1R proreceptor to mature IGF1R; dbSNP:rs121912429." id="VAR_034895" evidence="27">
<original>R</original>
<variation>Q</variation>
<location>
<position position="739"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34061581." id="VAR_034896">
<original>H</original>
<variation>R</variation>
<location>
<position position="808"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35224135." id="VAR_034897">
<original>A</original>
<variation>T</variation>
<location>
<position position="828"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs45611935." id="VAR_041426" evidence="30">
<original>N</original>
<variation>S</variation>
<location>
<position position="857"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts." id="VAR_076248" evidence="45">
<original>Y</original>
<variation>C</variation>
<location>
<position position="865"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; significant decrease in IGF1-induced DNA synthesis and AKT1 phosphorylation in patient fibroblasts." id="VAR_076249" evidence="45">
<original>R</original>
<variation>S</variation>
<location>
<position position="1256"/>
</location>
</feature>
<feature type="sequence variant" description="In IGF1RES; a benign mutation or a rare polymorphism, significant decrease in IGF1-induced DNA synthesis; significant increase in IGF1-induced AKT1 phosphorylation in patient fibroblasts; dbSNP:rs141802822." id="VAR_076250" evidence="45">
<original>R</original>
<variation>C</variation>
<location>
<position position="1337"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34102392." id="VAR_041427" evidence="30">
<original>A</original>
<variation>T</variation>
<location>
<position position="1338"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung squamous cell carcinoma sample; somatic mutation." id="VAR_041428" evidence="30">
<original>A</original>
<variation>V</variation>
<location>
<position position="1347"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10." evidence="16 47">
<original>Y</original>
<variation>F</variation>
<location>
<position position="980"/>
</location>
</feature>
<feature type="mutagenesis site" description="Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1." evidence="47">
<original>K</original>
<variation>A</variation>
<location>
<position position="1033"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on GRB10-binding." evidence="16">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1280"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on GRB10-binding." evidence="16">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1281"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of GRB10-binding." evidence="16">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1346"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; BAG11657." ref="3" evidence="59">
<original>TG</original>
<variation>R</variation>
<location>
<begin position="928"/>
<end position="929"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="37"/>
<end position="41"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="43"/>
<end position="49"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="53"/>
<end position="57"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="59"/>
<end position="65"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="68"/>
<end position="70"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="80"/>
<end position="83"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="85"/>
<end position="92"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="96"/>
<end position="98"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="115"/>
<end position="121"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="138"/>
<end position="144"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="157"/>
<end position="160"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="164"/>
<end position="166"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="168"/>
<end position="171"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="175"/>
<end position="178"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="183"/>
<end position="188"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="194"/>
<end position="199"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="201"/>
<end position="203"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="205"/>
<end position="209"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="217"/>
<end position="219"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="235"/>
<end position="241"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="247"/>
<end position="255"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="257"/>
<end position="263"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="269"/>
<end position="271"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="272"/>
<end position="274"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="275"/>
<end position="277"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="279"/>
<end position="283"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="297"/>
<end position="299"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="302"/>
<end position="306"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="311"/>
<end position="315"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="321"/>
<end position="323"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="325"/>
<end position="327"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="331"/>
<end position="341"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="345"/>
<end position="347"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="349"/>
<end position="352"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="354"/>
<end position="362"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="375"/>
<end position="378"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="383"/>
<end position="386"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="388"/>
<end position="392"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="415"/>
<end position="417"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="418"/>
<end position="423"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="434"/>
<end position="436"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="440"/>
<end position="443"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="445"/>
<end position="451"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="456"/>
<end position="466"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="474"/>
<end position="477"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="479"/>
<end position="481"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="724"/>
<end position="730"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="980"/>
<end position="982"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="983"/>
<end position="985"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="990"/>
<end position="992"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="996"/>
<end position="998"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="999"/>
<end position="1007"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1009"/>
<end position="1022"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1025"/>
<end position="1034"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="1037"/>
<end position="1039"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1041"/>
<end position="1053"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1054"/>
<end position="1056"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1065"/>
<end position="1069"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1071"/>
<end position="1074"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1076"/>
<end position="1080"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1087"/>
<end position="1100"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1109"/>
<end position="1128"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1138"/>
<end position="1140"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1141"/>
<end position="1143"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1149"/>
<end position="1151"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="1155"/>
<end position="1157"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1159"/>
<end position="1164"/>
</location>
</feature>
<feature type="turn" evidence="7">
<location>
<begin position="1165"/>
<end position="1167"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1168"/>
<end position="1170"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1171"/>
<end position="1174"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1176"/>
<end position="1178"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1181"/>
<end position="1186"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1191"/>
<end position="1207"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="1212"/>
<end position="1215"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1218"/>
<end position="1226"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1239"/>
<end position="1248"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1253"/>
<end position="1255"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1259"/>
<end position="1266"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1267"/>
<end position="1269"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="1274"/>
<end position="1277"/>
</location>
</feature>
<feature type="turn" evidence="8">
<location>
<begin position="1279"/>
<end position="1281"/>
</location>
</feature>
<feature type="turn" evidence="7">
<location>
<begin position="1283"/>
<end position="1285"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="1286"/>
<end position="1288"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1IGR"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1P4O"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2OJ9"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2ZM3"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3D94"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3F5P"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3LVP"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3O23"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4XSS"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000250"/>
<evidence key="11" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q60751"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000255"/>
<evidence key="13" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00316"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10454568"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11071852"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11591350"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11694888"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11884618"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12019176"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12556535"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12821780"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14657428"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14729630"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15878855"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15928254"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15998644"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17317169"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17524361"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1846292"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18501599"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18566589"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19041240"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19578119"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19778024"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20545947"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20596523"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20675137"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21414779"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21441024"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21994939"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22351760"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25040157"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2877871"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7541045"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7679099"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8247543"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8257688"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9202395"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9355755"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9581554"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9690478"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9727029"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9822622"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source ref="4"/>
</evidence>
<evidence key="58" type="ECO:0000269">
<source ref="52"/>
</evidence>
<evidence key="59" type="ECO:0000305"/>
<evidence key="60" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="7541045"/>
</source>
</evidence>
<sequence length="1367" mass="154793" checksum="AE8A735F87F745C8" modified="1988-08-01" version="1" precursor="true">
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>